莱克萨利亚的技术提高了大鼠脑中的塞马格卢提德水平, Lexaria's tech boosted brain levels of semaglutide in rats, hinting at improved GLP-1 drug effectiveness.

Lexaria生物科学公司报告了一项鼠类研究的可喜结果,该研究显示,其脱水TECH处理的微硫化物(FTS)与传统的口服微硫化物和控制组相比,达到了较高的大脑水平。 Lexaria Bioscience Corp. reported promising results from a rodent study showing its DehydraTECH-processed semaglutide (FTS) achieved higher brain levels compared to conventional oral semaglutide and control groups. 调查结果表明,这种技术可以加强生物分配,有可能提高GLP-1药物的功效和安全性。 The findings suggest the technology may enhance biodistribution, potentially improving the efficacy and safety of GLP-1 drugs. Lexaria计划开展进一步研究和行业合作,以开发更安全、更有效的治疗方法。 Lexaria plans further research and industry collaborations to develop safer, more effective treatments.